Search

Your search keyword '"Miyagawa, Ippei"' showing total 220 results
Start Over Author "Miyagawa, Ippei"
220 results on '"Miyagawa, Ippei"'

3. Tibia Cortical Bone Segmentation in Micro-CT and X-ray Microscopy Data Using a Single Neural Network

Author

Aust, Oliver, Thies, Mareike, DanielaWeidner, FabianWagner, Pechmann, Sabrina, Mill, Leonid, Andreev, Darja, Miyagawa, Ippei, Krönke, Gerhard, Christiansen, Silke, Uderhardt, Stefan, Maier, Andreas, Grüneboom, Anika, Gesellschaft für Informatik e.V. (GI), Maier-Hein, Klaus, editor, Deserno, Thomas M., editor, Handels, Heinz, editor, Maier, Andreas, editor, Palm, Christoph, editor, and Tolxdorff, Thomas, editor

Published
2022
Full Text
View/download PDF

7. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.

Author

Miyazaki, Yusuke, Funada, Masashi, Nakayamada, Shingo, Sonomoto, Koshiro, Tanaka, Hiroaki, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Yamaguchi, Ayako, Miyagawa, Ippei, Todoroki, Yasuyuki, Ueno, Masanobu, and Tanaka, Yoshiya

Subjects
THERAPEUTIC use of monoclonal antibodies, PATIENT safety, IMMUNOSUPPRESSIVE agents, RESEARCH funding, SCIENTIFIC observation, PROBABILITY theory, SYSTEMIC lupus erythematosus, RETROSPECTIVE studies, DESCRIPTIVE statistics, DRUG efficacy, COMPARATIVE studies, PATIENT aftercare, GLUCOCORTICOIDS, EVALUATION
Abstract

Objective To determine the safety and efficacy of anifrolumab in patients with systemic lupus erythematosus (SLE) classified based on the Lupus Low Disease Activity State (LLDAS) in real-world clinical practice. Methods This retrospective observational study involved SLE patients who started anifrolumab therapy. The primary end point was the retention rate over 26 weeks after initiating anifrolumab therapy; 45 patients followed up for 12 weeks or longer were analysed in the following groups to determine the safety and efficacy up to week 12 after treatment initiation: (i) non-LLDAS achievement group and (ii) minor flare group. Safety and efficacy were compared between the minor flare group and the standard of care (SoC) group (treated by adding glucocorticoids [GCs] or immunosuppressants) after adjustment with inverse probability of treatment weighting using propensity score (PS-IPTW). Results The retention rate of anifrolumab was 89.7% at week 26.The LLDAS achievement rates at week 12 were 42.9% and 66.7% in the non-LLDAS achievement and minor flare groups, respectively. In both groups, GC doses and SELENA–SLEDAI score significantly decreased. When the anifrolumab group with minor flare was compared with the SoC group or the GC dose increase group, the GC dose and SLEDAI score were significantly lower in the anifrolumab group than in either of the other groups; there was no significant difference in LLDAS achievement. Conclusion At week 26 after initiating anifrolumab therapy, ∼90% of patients remained on therapy. Anifrolumab might lower disease activity without initiating GCs and reduce GC doses, especially in patients who experience minor flares after LLDAS achievement. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. CCL19‐Positive Lymph Node Stromal Cells Govern the Onset of Inflammatory Arthritis via Tropomyosin Receptor Kinase

Author

Schälter, Fabian, primary, Azizov, Vugar, additional, Frech, Michael, additional, Dürholz, Kerstin, additional, Schmid, Eva, additional, Hendel, Anna, additional, Sarfati, Ilann, additional, Maeda, Yuichi, additional, Sokolova, Maria, additional, Miyagawa, Ippei, additional, Focke, Kristin, additional, Sarter, Kerstin, additional, van Baarsen, Lisa G. M., additional, Krautwald, Stefan, additional, Schett, Georg, additional, and Zaiss, Mario M., additional

Published
2024
Full Text
View/download PDF

11. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry

Author

Miyazaki, Yusuke, primary, Funada, Masashi, additional, Nakayamada, Shingo, additional, Sonomoto, Koshiro, additional, Tanaka, Hiroaki, additional, Hanami, Kentaro, additional, Fukuyo, Shunsuke, additional, Kubo, Satoshi, additional, Yamaguchi, Ayako, additional, Miyagawa, Ippei, additional, Todoroki, Yasuyuki, additional, Ueno, Masanobu, additional, and Tanaka, Yoshiya, additional

Published
2023
Full Text
View/download PDF

12. Association of frailty on treatment outcomes among patients with suspected infection treated at emergency departments

Author

Ishikawa, Shigeto, Miyagawa, Ippei, Kusanaga, Masashi, Abe, Toshikazu, Shiraishi, Atsushi, Fujishima, Seitaro, Ogura, Hiroshi, Saitoh, Daizoh, Kushimoto, Shigeki, Shiino, Yasukazu, Hifumi, Toru, Otomo, Yasuhiro, Okamoto, Kohji, Kotani, Joji, Sakamoto, Yuichiro, Sasaki, Junichi, Shiraishi, Shin-ichiro, Takuma, Kiyotsugu, Hagiwara, Akiyoshi, Yamakawa, Kazuma, Takeyama, Naoshi, Gando, Satoshi, and Mayumi, Toshihiko

Published
2021
Full Text
View/download PDF

22. Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD

Author

Todoroki, Yasuyuki, primary, Kubo, Satoshi, additional, Nakano, Kazuhisa, additional, Miyazaki, Yusuke, additional, Ueno, Masanobu, additional, Satoh-Kanda, Yurie, additional, Kanda, Ryuichiro, additional, Miyagawa, Ippei, additional, Hanami, Kentaro, additional, Nakatsuka, Keisuke, additional, Saito, Kazuyoshi, additional, Nakayamada, Shingo, additional, and Tanaka, Yoshiya, additional

Published
2022
Full Text
View/download PDF

23. Additional file 11 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 11: Supplementary Table S6. Comparison of activated Th1 and Th17 between PPPASI-50/75/90 responder and non-responder in PAO. Data are shown by median(quartile). P values were determined by Wilcoxon rank sum test. p*

Published
2022
Full Text
View/download PDF

25. Additional file 8 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 8: Supplementary Table S3. Correlation between changes in each immunophenotype and in the PPPASI. Spearman’s rank correlation coefficient.

Published
2022
Full Text
View/download PDF

26. Additional file 7 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 7: Supplementary Table S2. Comparison of activated Th1 and Th17 at baseline between with DMARDs group (N = 16) and without DMARDs group (N = 6). Data are shown by median(quartile) or n (%). P values were determined by the Wilcoxon rank sum test. p*

Published
2022
Full Text
View/download PDF

27. Additional file 4 of Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Author

Miyagawa, Ippei, Nakayamada, Shingo, Ueno, Masanobu, Miyazaki, Yusuke, Iwata, Shigeru, Kubo, Satoshi, Sonomoto, Koshiro, Anan, Junpei, Ohkubo, Naoaki, Inoue, Yoshino, and Tanaka, Yoshiya

Abstract

Additional file 4: Supplementary Table S3. Baseline predictive serum cytokine of MDA/DAPSA-remission/PASI90 by IL-17 or TNF-i analyzed by univariate analysis.

Published
2022
Full Text
View/download PDF

28. Additional file 3 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 3: Figure S3. Impact of guselkumab treatment on peripheral blood immune phenotypes. Changes in the proportion of A. CD4+ T cells subsets to CD3+ and CD4+ T cells (%), B. CD8+ T cells subsets to CD3+ and CD8+ T cells (%), C. a)-e) Activated CD4+ T cells to CD3+ and CD4+ T cells (%) f) Activated CD8+ T cells to CD3+ and CD8+ T cells (%), D. B cells subsets to CD3- and CD19+ B cells (%), E. Classical and non-classical monocytes to CD3-, CD19-, CD20- and CD14+ cells (%), F. Myeloid and Plasmacytoid DCs to CD3-, CD19-, CD20- CD14- and human leukocyte antigen-DR+ cells (%), G. CD16+ and CD16- NK cells to CD3-, CD19-, CD20- CD14- and CD56+ cells(%). *p

Published
2022
Full Text
View/download PDF

29. Additional file 2 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 2: Figure S2. Comparison of treatment response at month 1 and 3. A. Rate of DAPSA-LDA Responders (%) B. Rate of DAPSA-REM Responders C. Rate of PPPASI-50 Responders (%) D. Rate of PPPASI-75 Responders E. Rate of PPPASI-90 Responders (%) at month q1 and 3. *p

Published
2022
Full Text
View/download PDF

30. Additional file 2 of Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Author

Miyagawa, Ippei, Nakayamada, Shingo, Ueno, Masanobu, Miyazaki, Yusuke, Iwata, Shigeru, Kubo, Satoshi, Sonomoto, Koshiro, Anan, Junpei, Ohkubo, Naoaki, Inoue, Yoshino, and Tanaka, Yoshiya

Abstract

Additional file 2: Supplementary Table S1. Baseline characteristics of the patients in cohort 1.

Published
2022
Full Text
View/download PDF

31. Additional file 3 of Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Author

Miyagawa, Ippei, Nakayamada, Shingo, Ueno, Masanobu, Miyazaki, Yusuke, Iwata, Shigeru, Kubo, Satoshi, Sonomoto, Koshiro, Anan, Junpei, Ohkubo, Naoaki, Inoue, Yoshino, and Tanaka, Yoshiya

Abstract

Additional file 3: Supplementary Table S2. Comparison of 1 year treatment response between TNF-i and IL-17-i in cohort 1.

Published
2022
Full Text
View/download PDF

32. Additional file 5 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 5: Figure S5. Changes in serum TNF-α and IL-17 concentration during 6 months of treatment. TNF-α (pg/ml), B. IL-17A (fg/ml). *p

Published
2022
Full Text
View/download PDF

34. Additional file 4 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 4: Figure S4. Impact of adalimumab treatment on peripheral blood immune phenotypes. Changes in the proportion of A. CD4+ T cells subsets to CD3+ and CD4+ T cells (%), B. CD8+ T cells subsets to CD3+ and CD8+ T cells (%), C. a)-c) Activated CD4+ T cells to CD3+ and CD4+ T cells (%) d) Activated CD8+ T cells to CD3+ and CD8+ T cells (%), D. B cells subsets to CD3- and CD19+ B cells (%), E. Classical and non-classical monocytes to CD3-, CD19-, CD20- and CD14+ cells (%), F. Myeloid and Plasmacytoid DCs to CD3-, CD19-, CD20- CD14- and human leukocyte antigen-DR+ cells (%), G. CD16+ and CD16- NK cells to CD3-, CD19-, CD20- CD14- and CD56+ cells(%). *p

Published
2022
Full Text
View/download PDF

35. Additional file 5 of Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Author

Miyagawa, Ippei, Nakayamada, Shingo, Ueno, Masanobu, Miyazaki, Yusuke, Iwata, Shigeru, Kubo, Satoshi, Sonomoto, Koshiro, Anan, Junpei, Ohkubo, Naoaki, Inoue, Yoshino, and Tanaka, Yoshiya

Abstract

Additional file 5: Supplementary Table S4. Comparison of baseline characteristics between IL-22 high and low group.

Published
2022
Full Text
View/download PDF

36. Additional file 9 of Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Author

Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, and Tanaka, Yoshiya

Abstract

Additional file 9: Supplementary Table S4. Correlation between changes in each immunophenotype and in the DAPSA. Spearman’s rank correlation coefficient.

Published
2022
Full Text
View/download PDF

37. Impact of serum interleukin 22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: A retrospective study

Author

Miyagawa, Ippei, primary, Nakayamada, Shingo, additional, Ueno, Masanobu, additional, Miyazaki, Yusuke, additional, Iwata, Shigeru, additional, Kubo, Satoshi, additional, Sonomoto, Koshiro, additional, Anan, Junpei, additional, Ohkubo, Naoaki, additional, Inoue, Yoshino, additional, and Tanaka, Yoshiya, additional

Published
2022
Full Text
View/download PDF

38. Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis

Author

Ohkubo, Naoaki, primary, Iwata, Shigeru, additional, Nakano, Kazuhisa, additional, Miyagawa, Ippei, additional, Hanami, Kentaro, additional, Fukuyo, Shunsuke, additional, Miyazaki, Yusuke, additional, Kawabe, Akio, additional, Nakayamada, Shingo, additional, and Tanaka, Yoshiya, additional

Published
2021
Full Text
View/download PDF

40. Bimekizumab, a Humanized Monoclonal Immunoglobulin G1 Antibody for the Treatment of Psoriatic Arthritis: A Systematic Review.

Author

Miyagawa, Ippei and Tanaka, Yoshiya

Subjects
*PSORIATIC arthritis, *DRUG accessibility, *ANTIRHEUMATIC agents, *JANUS kinases, *DRUG bioavailability, *IMMUNOGLOBULINS
Abstract

Psoriatic arthritis (PsA), often accompanied by nail psoriasis, spine, enthesitis and iritis, is a typical complication of psoriasis. PsA leads to the destruction and/or ankylosis of the peripheral joints or spine, resulting in poor quality of life. Interleukin (IL)-23, IL-17 and tumour necrosis factor play pivotal roles in the pathogenesis of PsA and are targets for its treatment. Biological disease-modifying antirheumatic drugs targeting these cytokines and targeted synthetic disease-modifying antirheumatic drugs targeting Janus kinases are available and widely used in clinical practice. Despite the availability of these drugs, there are still unmet needs; for example, patients often resist treatment and relapse or develop intolerance. Bimekizumab is a humanized monoclonal IgG1 antibody that selectively and directly inhibits IL-17A and IL-17F expression. Recently, the efficacy and tolerability of bimekizumab have been reported in several large clinical trials, including two phase III studies. Bimekizumab brings rapid symptom relief and is effective in patients who are biologic-naïve and those who have inadequate responses or become intolerable to tumour necrosis factor inhibitors and require discontinuation; therefore, it is expected to be a novel blockbuster to overcome the unmet needs of PsA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Safety and Effectiveness of Mepolizumab Therapy in Remission Induction Therapy for Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study

Author

Ueno, Masanobu, primary, Miyagawa, Ippei, additional, Aritomi, Takafumi, additional, Kimura, Koichi, additional, Iwata, Shigeru, additional, Hanami, Kentaro, additional, Fukuyo, Shunsuke, additional, Kubo, Satoshi, additional, Miyazaki, Yusuke, additional, Nakayamada, Shingo, additional, and Tanaka, Yoshiya, additional

Published
2021
Full Text
View/download PDF

43. Additional file 1 of Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

Author

Miyazaki, Yusuke, Nakano, Kazuhisa, Nakayamada, Shingo, Kubo, Satoshi, Iwata, Shigeru, Hanami, Kentaro, Fukuyo, Shunsuke, Miyagawa, Ippei, Yamaguchi, Ayako, Kawabe, Akio, Saito, Kazuyoshi, and Tanaka, Yoshiya

Abstract

Additional files 1: Supplementary Figure S1. Continuous rates for 12 weeks after CZP initiation as Kaplan-Meier curves. The continuation rate through 12 weeks of CZP treatment was shown.

Published
2021
Full Text
View/download PDF

44. Additional file 2 of Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

Author

Miyazaki, Yusuke, Nakano, Kazuhisa, Nakayamada, Shingo, Kubo, Satoshi, Iwata, Shigeru, Hanami, Kentaro, Fukuyo, Shunsuke, Miyagawa, Ippei, Yamaguchi, Ayako, Kawabe, Akio, Saito, Kazuyoshi, and Tanaka, Yoshiya

Abstract

Additional files 2: Supplementary Table S1. Reasons for discontinuing CZP. Supplementary Table S2. Relation of serum levels of TNF and IL-6 to clinical signs and laboratory data at baseline. Supplementary Table S3. Relation of serum CZP concentrations at 24 and 48 hours after the first administration to clinical signs and laboratory data at baseline. Supplementary Table S4. Predictive factors for serum TNFα levels at 24 hours identified by simple and multiple regression analysis. Supplementary Table S5. Predictive factors for serum TNFα levels

Published
2021
Full Text
View/download PDF

46. Effectiveness and Safety of Mepolizumab in Combination with Corticosteroids in Patients with Eosinophilic Granulomatosis with Polyangiitis

Author

Ueno, Masanobu, primary, Miyagawa, Ippei, additional, Nakano, Kazuhisa, additional, Iwata, Shigeru, additional, Hanami, Kentaro, additional, Fukuyo, Shunsuke, additional, Kubo, Satoshi, additional, Miyazaki, Yusuke, additional, Kawabe, Akio, additional, Yoshinari, Hiroko, additional, Nakayamada, Shingo, additional, and Tanaka, Yoshiya, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results